

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

U-251MG

RRID:CVCL_0021

Type: Cell Line

Proper Citation

RRID:CVCL_0021

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0021

Proper Citation: RRID:CVCL_0021

Description: Cell line U-251MG is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Astrocytoma

Defining Citation: [PMID:77569](#), [PMID:450131](#), [PMID:608846](#), [PMID:833871](#), [PMID:2041050](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:3675803](#), [PMID:4134536](#), [PMID:4369403](#), [PMID:6260907](#), [PMID:6582512](#), [PMID:7693337](#), [PMID:7763724](#), [PMID:8104691](#), [PMID:8878451](#), [PMID:9090379](#), [PMID:9220028](#), [PMID:9230885](#), [PMID:9331090](#), [PMID:9614553](#), [PMID:9842975](#), [PMID:10416987](#), [PMID:10551321](#), [PMID:10560660](#), [PMID:10700174](#), [PMID:14614447](#), [PMID:14655754](#), [PMID:15748285](#), [PMID:15900046](#), [PMID:16232199](#), [PMID:16391870](#), [PMID:16697959](#), [PMID:16957166](#), [PMID:17088437](#), [PMID:17595512](#), [PMID:19372543](#), [PMID:19435942](#), [PMID:20215515](#), [PMID:20593219](#), [PMID:22068913](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22570425](#), [PMID:22628656](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:24810477](#), [PMID:25894527](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27582061](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:29716531](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:33385022](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: JFCR39 cancer cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: U-251MG

Synonyms: U-251 MG, U-251-MG, U-251_MG, U251-MG, U251MG, U-251, U251, U251n, U251N, 251 MG, 251MG, 251 MG(6)

Cross References: BTO:BTO_0002035, CLO:CLO_0009456, EFO:EFO_0006498, CLDB:cl4583, AddexBio:C0005029/5016, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:351, BioSample:SAMN10988290, cancercellines:CVCL_0021, CCRID:1101HUM-PUMC000058, CCRID:3101HUMTCHu58, CCRID:4201HUM-CCTCC000093, CCTCC:GDC0093, Cell_Model_Passport:SIDM00111, CGH-DB:155-1, ChEMBL-Cells:ChEMBL3307756, ChEMBL-Targets:ChEMBL615022, CLS:300385, Cosmic:687451, Cosmic:848340, Cosmic:849850, Cosmic:850742, Cosmic:875896, Cosmic:897440, Cosmic:905983, Cosmic:920818, Cosmic:923899, Cosmic:970094, Cosmic:974243, Cosmic:1044250, Cosmic:1066235, Cosmic:1092644, Cosmic:1171225, Cosmic:1175823, Cosmic:1217673, Cosmic:1312345, Cosmic:1436038, Cosmic:1610741, Cosmic:1998487, Cosmic:2367502, Cosmic:2367554, Cosmic:2516042, Cosmic:2550363, Cosmic:2580916, Cosmic-CLP:905983, DepMap:ACH-000232, ECACC:09063001, EGA:EGAS00001000978, GDSC:905983, GEO:GSE66597, GEO:GSM2103, GEO:GSM50180, GEO:GSM50244, GEO:GSM101675, GEO:GSM101677, GEO:GSM101678, GEO:GSM101679, GEO:GSM101680, GEO:GSM101685, GEO:GSM743440, GEO:GSM750795, GEO:GSM799328, GEO:GSM799391, GEO:GSM844718, GEO:GSM844719, GEO:GSM847166, GEO:GSM887720, GEO:GSM888814, GEO:GSM1153398, GEO:GSM1178662, GEO:GSM1178663, GEO:GSM1181247, GEO:GSM1181342, GEO:GSM1670555, GEO:GSM2124691, GEO:GSM7701412, GEO:GSM7701413, Hysigen:TCH-C366, IARC_TP53:2575, ICLC:HTL99014, JCRB:IFO50288, KCB:KCB 200965YJ, Kerafast:EDK001, LiGeA:CCLE_040, LINCS_LDP:LCL-1400, Lonza:105, Lonza:1007, MetaboLights:MTBLS6212, NCI-DTP:U-251, PharmacDB:U251MG_1629_2019, PRIDE:PXD000589, PRIDE:PXD003539, PRIDE:PXD005940, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_0021, PubChem_Cell_line:CVCL_0021, RCB:RCB0461, SKY/M-FISH/CGH:2825, TOKU-E:4005, Ubigen:YC-D015, Wikidata:Q54973550

ID: CVCL_0021

Record Creation Time: 20220427T221639+0000

Record Last Update: 20260830T000146+0000

Ratings and Alerts

No rating or validation information has been found for U-251MG.

Warning: Discontinued: RCB; RCB0461

Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: JFCR39 cancer cell line panel., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 4639 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Li X, et al. (2026) Paeonol Inhibits Cell Growth by Inducing Ferroptosis in Human Glioma Cells. *Pharmacology research & perspectives*, 14(1), e70213.

Mao C, et al. (2026) Small Molecule Cocktail DLC79 Suppresses Gliomagenesis by Activating Ascl1 and Remodeling Transcriptome. *Cells*, 15(2).

Mansson LK, et al. (2026) Optogenetic Control of the Integrated Stress Response Limits Glioblastoma Invasion. *Cell biochemistry and function*, 44(4), e70212.

Zhao K, et al. (2026) Aromatic amino acid metabolism shapes autophagy-mediated adaptation to iron deprivation in glioblastoma cells. *Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine*, 39(3), 1167.

Gaiaschi L, et al. (2026) In Vitro Anti-Glioblastoma Activity of a Novel Pt(IV)-Ganoderic Acid A Conjugate. *International journal of molecular sciences*, 27(6).

Shen Y, et al. (2026) CCL1-AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages. *Cancer immunology research*, 14(4), 676.

Cheng M, et al. (2026) YTHDF3 facilitates DNA damage response by recognizing METTL3-mediated m6A modification to promote chemotherapy resistance in glioblastoma. *Cancer letters*, 649, 218445.

Rurka P, et al. (2026) A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma. *Molecular oncology*.

Zhang Z, et al. (2026) Machine learning model on multi-omics data enables risk stratification and identifies molecular heterogeneity and therapeutic targets in glioblastoma. *Molecular cancer*, 25(1).

Mendoza N, et al. (2026) Chemical Constituents of *Taxodium mucronatum* (Cupressaceae) and Some of Its Endophytic Fungi, and Their In Silico and In Vitro Evaluations as SARS-CoV-2 Inhibitors and as Cytotoxic Agents. *Chemistry & biodiversity*, 23(3), e03702.

Zhang Z, et al. (2026) A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. *Pharmaceuticals (Basel, Switzerland)*, 19(4).

Su H, et al. (2026) Lipid Droplet-Localized Spindle Apparatus Coiled-Coil Protein 1 Regulates Lipid Droplet Distribution. *Advanced science (Weinheim, Baden-Wurttemberg,*

Germany), e11960.

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. *Molecular cell*, 86(8), 1546.

Fu L, et al. (2026) Anti-Glioma Activity of Artejasminolide Isolated From *Artemisia argyi* Based on Bioactivity Evaluation and Network Pharmacology. *Chemistry & biodiversity*, 23(2), e03722.

Song J, et al. (2026) JOSD1 Deubiquitinates Twist1 and Facilitates Epithelial-Mesenchymal Transition in Glioblastoma. *Cell biochemistry and function*, 44(4), e70208.

Rahbarlayegh E, et al. (2026) Chronic IFN- γ Exposure Induces Divergent Adaptive Programs in Glioblastoma Subtypes. *Cancers*, 18(10).

Giannaki M, et al. (2026) Notch Overexpression Potentiates Interferon Signaling in Glioma Cells. *Current issues in molecular biology*, 48(6).

Jiang AYL, et al. (2026) Glioma chemotherapeutic resistance is tied to membrane electrophysiological properties and glycosylation. *Bioengineering & translational medicine*, 11(1), e70069.

Zhou S, et al. (2026) Vascular normalization by erianin unleashes CAR-T immunotherapy in glioblastoma. *Angiogenesis*, 29(2), 18.

Lu B, et al. (2026) Targeting the tumor microenvironment: reprogramming macrophages as a novel therapeutic strategy in FUOM-deficient glioblastoma. *Cell death & disease*, 17(1).